Tandem Diabetes Care, Inc. (NASDAQ:TNDM) investors will be delighted, with the company turning in some strong numbers with its latest results. Revenues of US$192m were better than expected, some 10% ahead of forecasts. The company still lost a statutory US$0.65 per share, although the losses were 16% smaller than the analysts expected. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.

See our latest analysis for Tandem Diabetes Care

Taking into account the latest results, the consensus forecast from Tandem Diabetes Care's 15 analysts is for revenues of US$869.7m in 2024. This reflects a meaningful 13% improvement in revenue compared to the last 12 months. Losses are predicted to fall substantially, shrinking 26% to US$1.62. Yet prior to the latest earnings, the analysts had been forecasting revenues of US$844.5m and losses of US$1.66 per share in 2024. It looks like there's been a modest increase in sentiment in the recent updates, with the analysts becoming a bit more optimistic in their predictions for both revenues and losses per share.

It will come as no surprise to learn thatthe analysts have increased their price target for Tandem Diabetes Care 22% to US$43.57on the back of these upgrades. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. There are some variant perceptions on Tandem Diabetes Care, with the most bullish analyst valuing it at US$60.00 and the most bearish at US$18.00 per share. Note the wide gap in analyst price targets? This implies to us that there is a fairly broad range of possible scenarios for the underlying business.

Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. The period to the end of 2024 brings more of the same, according to the analysts, with revenue forecast to display 18% growth on an annualised basis. That is in line with its 20% annual growth over the past five years. Compare this with the broader industry, which analyst estimates (in aggregate) suggest will see revenues grow 8.1% annually. So although Tandem Diabetes Care is expected to maintain its revenue growth rate, it's definitely expected to grow faster than the wider industry.

The Bottom Line

The most obvious conclusion is that the analysts made no changes to their forecasts for a loss next year. Pleasantly, they also upgraded their revenue estimates, and their forecasts suggest the business is expected to grow faster than the wider industry. We note an upgrade to the price target, suggesting that the analysts believes the intrinsic value of the business is likely to improve over time.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. At Simply Wall St, we have a full range of analyst estimates for Tandem Diabetes Care going out to 2026, and you can see them free on our platform here..

It is also worth noting that we have found 2 warning signs for Tandem Diabetes Care that you need to take into consideration.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.